- Company co-created and funded by Novo Holdings and HealthCap
- Breakthrough asset in-licensed from Norway’s foremost tech transfer office, Inven2
- João Ribas and Jørgen Søberg Petersen from Novo Seeds will join the Board of Directors
Copenhagen, Denmark, 2 June 2021 – Novo Holdings today announces that it has founded and invested in Tribune Therapeutics (“Tribune”), a company set up to exploit a novel, pan-antifibrotic mechanism across a wide range of indications. This follows a period of company creation, with close involvement by Novo Seeds, the early-stage investment and company creation team of Novo Holdings, in collaboration with HealthCap, one of the largest specialized providers of venture capital within life sciences in Europe.